Based on these results, a potential treatment of ccRCC patients with ADIPEG20, currently in clinical trials in a range of other cancer types (e.g., lung, liver and pancreatic cancers), should be carefully monitored since it might favor the selection of ASS1-proficient and more aggressive subpopulations from the primary tumor and could benefit from the combination of ASS1 inhibitors to target potentially metastatic clones. The gene discussed is ASS1; the disease is pancreatic neoplasm.